{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["24"],"submitter":["Nagpal R"],"pubmed_abstract":["<h4>Background</h4>The prognostic value of the Geriatric 8 (G8) screening score in metastatic renal cell carcinoma (mRCC) patients receiving first-line immunotherapy remains unclear. This study aimed to evaluate the prognostic role of G8 within the context of the Meet-URO classification in mRCC patients treated with first-line ipilimumab-nivolumab.<h4>Methods</h4>This retrospective multicentre study analysed 106 mRCC patients treated with first-line ipilimumab-nivolumab. G8 and Meet-URO scores were calculated before treatment initiation. Primary endpoint was overall survival (OS), defined as duration from first administration of Nivolumab to death. OS was analysed in relation to age groups, G8 scores, and Meet-URO score categories, with data censored for patients still alive at the last fo"],"journal":["Technology in cancer research & treatment"],"pagination":["15330338251316626"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11848895"],"repository":["biostudies-literature"],"pubmed_title":["Prognostic Value of G8 Geriatric Screening and Meet-URO Scores in Metastatic Renal Cell Carcinoma Patients Receiving First-Line Ipilimumab-Nivolumab Combination Immunotherapy."],"pmcid":["PMC11848895"],"pubmed_authors":["Rebuzzi SE","Nagpal R","Bimbatti D","Bracarda S","Calabro F","Fornarini G","Basso U","Rescigno P","Giannarelli D","Fratino L","Santoni M","Campione M","Rizzo M","Signori A","Banna GL","Giorgi U"],"additional_accession":[]},"is_claimable":false,"name":"Prognostic Value of G8 Geriatric Screening and Meet-URO Scores in Metastatic Renal Cell Carcinoma Patients Receiving First-Line Ipilimumab-Nivolumab Combination Immunotherapy.","description":"<h4>Background</h4>The prognostic value of the Geriatric 8 (G8) screening score in metastatic renal cell carcinoma (mRCC) patients receiving first-line immunotherapy remains unclear. This study aimed to evaluate the prognostic role of G8 within the context of the Meet-URO classification in mRCC patients treated with first-line ipilimumab-nivolumab.<h4>Methods</h4>This retrospective multicentre study analysed 106 mRCC patients treated with first-line ipilimumab-nivolumab. G8 and Meet-URO scores were calculated before treatment initiation. Primary endpoint was overall survival (OS), defined as duration from first administration of Nivolumab to death. OS was analysed in relation to age groups, G8 scores, and Meet-URO score categories, with data censored for patients still alive at the last fo","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Jan-Dec","modification":"2025-04-03T23:36:40.218Z","creation":"2025-04-03T23:36:40.218Z"},"accession":"S-EPMC11848895","cross_references":{"pubmed":["39989333"],"doi":["10.1177/15330338251316626"]}}